-
公开(公告)号：WO2010062715A2
公开(公告)日：2010-06-03
申请号：PCT/US2009/062966
申请日：2009-11-02
Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICAL USA, INC , VRASPIR, Pavel , GAVENDA, Ales , GABRIEL, Roman , JEGOROV, Alexandr
Inventor： VRASPIR, Pavel , GAVENDA, Ales , GABRIEL, Roman , JEGOROV, Alexandr
IPC: C07D417/12
CPC classification number: C07D417/12
Abstract: The present invention provides solvates of Dasatinib, crystalline forms of Dasatinib solvates and methods of their preparation.
Abstract translation: 本发明提供了达沙替尼的溶剂合物，达沙替尼溶剂化物的结晶形式及其制备方法。
-
公开(公告)号：WO2010062715A3
公开(公告)日：2010-11-18
申请号：PCT/US2009062966
申请日：2009-11-02
Applicant: TEVA PHARMA , TEVA PHARMACEUTICAL USA INC , VRASPIR PAVEL , GAVENDA ALES , GABRIEL ROMAN , JEGOROV ALEXANDR
Inventor： VRASPIR PAVEL , GAVENDA ALES , GABRIEL ROMAN , JEGOROV ALEXANDR
IPC: C07D417/12
CPC classification number: C07D417/12
Abstract: The present invention provides solvates of Dasatinib, crystalline forms of Dasatinib solvates and methods of their preparation.
Abstract translation: 本发明提供达沙替尼的溶剂合物，达沙替尼溶剂合物的结晶形式及其制备方法。
-
公开(公告)号：WO2010011834A2
公开(公告)日：2010-01-28
申请号：PCT/US2009051530
申请日：2009-07-23
Applicant: TEVA PHARMA , TEVA PHARMA , JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , CANAVESI AUGUSTO , SCARPITTA FRANCESCA
Inventor： JEGOROV ALEXANDR , GAVENDA ALES , VRASPIR PAVEL , CANAVESI AUGUSTO , SCARPITTA FRANCESCA
IPC: C07D403/06
CPC classification number: C07D403/06 , C07D209/12
Abstract: Polymorphs of sunitinib acetate and sunitinib base and sunitinib malate form 1 have been prepared and described.
Abstract translation: 已经制备和描述了舒尼替尼乙酸盐和舒尼替尼碱和苹果酸舒尼替尼形式的多晶型物。
-
公开(公告)号：WO2009053854A2
公开(公告)日：2009-04-30
申请号：PCT/IB2008/003862
申请日：2008-10-23
Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , SIMO, ondrej , FILIPCIK, Jiri , MARTAUS, Alexandr , JEGOROV, Alexandr , GAVENDA, Ales , ARONHIME, Judith , VRASPIR, Pavel , KOLTAI, Tamas , FAUSTMANN, Jiri , GABRIEL, Roman
Inventor： SIMO, ondrej , FILIPCIK, Jiri , MARTAUS, Alexandr , JEGOROV, Alexandr , GAVENDA, Ales , ARONHIME, Judith , VRASPIR, Pavel , KOLTAI, Tamas , FAUSTMANN, Jiri , GABRIEL, Roman
CPC classification number: C07D417/12
Abstract: Provided is dasatinib, solvates thereof and their crystalline forms, methods for their preparation, and pharmaceutical compositions thereof.
Abstract translation: 提供达沙替尼，其溶剂合物及其结晶形式，其制备方法及其药物组合物。
-
公开(公告)号：WO2011100325A3
公开(公告)日：2011-12-15
申请号：PCT/US2011024194
申请日：2011-02-09
Applicant: SICOR INC , VRASPIR PAVEL , PAIOCCHI MAURIZIO , JEGOROV ALEXANDR , SCARPITTA FRANCESCA
Inventor： VRASPIR PAVEL , PAIOCCHI MAURIZIO , JEGOROV ALEXANDR , SCARPITTA FRANCESCA
IPC: C07D403/06 , A61K31/404 , A61P35/00
CPC classification number: C07D403/06
Abstract: Polymorphs of Sunitinib malate and other salts have been prepared. Compositions comprising Sunitinib base, L-malic acid and another carboxylic acid are also described. Such polymorphs and compositions are useful, for example, in preparing pharmaceutical compositions.
Abstract translation: 已经制备了苹果酸舒尼替尼和其他盐的多晶型物。 还描述了包含舒尼替尼碱，L-苹果酸和另一种羧酸的组合物。 这样的多晶型物和组合物例如在制备药物组合物中是有用的。
-
Patent Agency Ranking6.发明申请
公开(公告)号：WO2010011834A3
公开(公告)日：2010-01-28
申请号：PCT/US2009/051530
申请日：2009-07-23
Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , JEGOROV, Alexandr , GAVENDA, Ales , VRASPIR, Pavel , CANAVESI, Augusto , SCARPITTA, Francesca
Inventor： JEGOROV, Alexandr , GAVENDA, Ales , VRASPIR, Pavel , CANAVESI, Augusto , SCARPITTA, Francesca
IPC: C07D403/06
Abstract: Process for the preparation of sunitinib malate form I via sunitinib acetate and polymorphs of said intermediate.
-
公开(公告)号：WO2010005924A1
公开(公告)日：2010-01-14
申请号：PCT/US2009/049748
申请日：2009-07-07
Applicant: PLUS CHEMICALS SA , TEVA PHARMACEUTICALS USA, INC. , GAVENDA, Ales , VRASPIR, Pavel , CANAVESI, Augusto , ARONHIME, Judith , BIGATTI, Ettore , FAUSTMANN, Jiri , JEGOROV, Alexandr , STEPHENS, Peter, W. , LUX, Giovanna , PAIOCCHI, Maurizio
Inventor： GAVENDA, Ales , VRASPIR, Pavel , CANAVESI, Augusto , ARONHIME, Judith , BIGATTI, Ettore , FAUSTMANN, Jiri , JEGOROV, Alexandr , STEPHENS, Peter, W. , LUX, Giovanna , PAIOCCHI, Maurizio
IPC: C07D239/94
CPC classification number: C07D239/94
Abstract: The preparation of crystalline Erlotinib base form G2 is described. This crystalline form can be converted to an Erlotinib salt, such as Erlotinib HCl, which can be used in the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC).
Abstract translation: 描述了结晶埃罗替尼碱基形式G2的制备。 该结晶形式可转化为埃洛替尼盐，如盐酸埃洛替尼，可用于治疗局部晚期或转移性非小细胞肺癌（NSCLC）患者。
-
8.发明申请SUNITINIB HEMI-L-MALATE, POLYMORPHS AND PREPARATION THEREOF, POLYMORPHS OF RACEMIC SUNITINIB MALATE, COMPOSITINS CONTAINING SUNITINIB BASE AND MALIC ACID AND PREPARATION THEREOF 审中-公开顺丁烯二酸-L-马来酸酯，多晶型物及其制备，狂犬病的马来酸赛尼替丁的多晶型物，含有顺丁尼特基和马来酸的复合物及其制备方法
公开(公告)号：WO2009067686A2
公开(公告)日：2009-05-28
申请号：PCT/US2008/084386
申请日：2008-11-21
Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , JEGOROV, Alexandr , VRASPIR, Pavel , ARONHIME, Judith , GAVENDA, Ales , ANGIOLETTI, Paolo , MACDONALD, Peter, Lindsay , SCARPITTA, Francesca , VILLA, Marco , BIGATTI, Ettore , CANAVESI, Augusto
Inventor： JEGOROV, Alexandr , VRASPIR, Pavel , ARONHIME, Judith , GAVENDA, Ales , ANGIOLETTI, Paolo , MACDONALD, Peter, Lindsay , SCARPITTA, Francesca , VILLA, Marco , BIGATTI, Ettore , CANAVESI, Augusto
IPC: C07D403/06 , A61K31/404 , A61P35/00
CPC classification number: C07D403/06
Abstract: The invention provides Sunitinib hemi-L-malate, polymorphs thereof, polymorphs of racemic sunitinib malate, compositions containing sunitinib base and either L or racemic malic acid, processes for the preparation thereof, and pharmaceutical compositions thereof.
Abstract translation: 本发明提供舒尼替尼半-L-苹果酸盐，其多晶型物，外消旋苹果酸舒尼替尼的多晶型物，含舒尼替尼碱和L或外消旋苹果酸的组合物，其制备方法及其药物组合物。
-
9.发明申请
公开(公告)号：WO2009067674A2
公开(公告)日：2009-05-28
申请号：PCT/US2008/084366
申请日：2008-11-21
Applicant: TEVA PHARMACEUTICAL INDUSTRIES LTD. , TEVA PHARMACEUTICALS USA, INC. , GAVENDA, Ales , BIGATTI, Ettore , JEGOROV, Alexandr , CANAVESI, Augusto , VRASPIR, Pavel , ARONHIME, Judith , MACDONALD, Peter, Lindsay , SCARPITTA, Francesca , VILLA, Marco , ANGIOLETTI, Paolo
Inventor： GAVENDA, Ales , BIGATTI, Ettore , JEGOROV, Alexandr , CANAVESI, Augusto , VRASPIR, Pavel , ARONHIME, Judith , MACDONALD, Peter, Lindsay , SCARPITTA, Francesca , VILLA, Marco , ANGIOLETTI, Paolo
IPC: C07D403/06 , A61K31/404 , A61P35/00
CPC classification number: C07D403/06
Abstract: The present invention provides polymorphs of Sunitinib base and processes for preparation thereof.
Abstract translation: 本发明提供舒尼替尼碱的多晶型物及其制备方法。
-
10.发明申请
公开(公告)号：WO2013134534A2
公开(公告)日：2013-09-12
申请号：PCT/US2013/029664
申请日：2013-03-07
Applicant: PLUS CHEMICALS S.A. , TEVA PHARMACEUTICALS USA, INC. , VRASPIR, Pavel , JEGOROV, Alexandr , GABRIEL, Roman , GAVENDA, Ales
Inventor： VRASPIR, Pavel , JEGOROV, Alexandr , GABRIEL, Roman , GAVENDA, Ales
IPC: C07D305/14
CPC classification number: C07D305/14 , C07B2200/13
Abstract: The invention relates to solid state forms of Cabazitaxel and processes for preparing the solid state forms. The invention further relates to pharmaceutical compositions and formulations comprising one or more of the solid state forms.
Abstract translation: 本发明涉及卡巴他赛的固态形式和制备固态形式的方法。 本发明还涉及包含一种或多种固态形式的药物组合物和制剂。
-
-
-
-
-
-
-
-
-
Search Results
21
records
(took 0.01 seconds)
